Anti-cancer effect of the combination of thiacremonone and docetaxel by inactivation of NF-κB in human cancer cells

Biomolecules and Therapeutics

Volumn 17, Issue 4, 2009, Pages 403-411

  Ban, Jung Ok ^a   Cho, Jin Suk ^a   Hwang, In Guk ^a   Noh, Jin Woo ^a   Kim, Wun Jae ^a   Lee, Ung Soo ^a   Moon, Dong Cheul ^a   Jeong, Heon Sang ^a   Lee, Hee Soon ^a   Hwang, Bang Yeon ^a   Jung, Jae Kyung ^a   Han, Sang Bae ^a   Hong, Jin Tae ^a  

^a Chungju National University   (South Korea)

Author keywords

Apoptotic cell death; Docetaxel; NF B; Prostate cancer; Thiacremonone

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; DOCETAXEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; SULFUR DERIVATIVE; THIACREMONONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; GENE TARGETING; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; PROSTATE CANCER;

ALLIUM SATIVUM;

EID: 73449121119     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2009.17.4.403     Document Type: Article

References (38)

1. Andrzejewski, T., Deeb, D., Gao, X., Danyluk, A., Arbab, A. S., Dulchavsky, S. A. and Gautam S. C. (2008). Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol. Res. 17, 257-267.
2. Ban, J. O., Lee, H. S., Jeong, H. S., Song, S., Hwang, B. Y., Moon, D. C., Yoon, D. Y., Han, S. B. and Hong, J. T. (2009). Thiacremonone augments chemotherapeutic agent-induced growth inhibition in human colon cancer cells through inactivation of nuclear factor-{kappa}B. Mol. Cancer Res. 7, 870-879.
3. Ban, J. O., Yuk, D. Y., Woo, K. S., Kim, T. M., Lee, U. S., Jeong, H. S., Kim, D. J., Chung, Y. B., Hwang, B. Y., Oh, K. W. and Hong, J. T. (2007) Inhibition of cell growth and induction of apoptosis via inactivation of NF-kappaB by a sulfurcompound isolated from garlic in human colon cancer cells. J. Pharmacol. Sci. 104, 374-383.
4. Baker, J., Ajani, J., Scotté, F., Winther, D., Martin, M., Aapro, M. S. and von Minckwitz, G. (2009). Docetaxel-related side effects and their management. Eur. J. Oncol. Nurs. 13, 49-59.
5. Barkett, M. and Gilmore, T. D. (1999). Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18, 6910-6924.
6. Chuang, S. E., Yeh, P. Y. and Lu, Y. S. (2002). Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem. Pharmacol. 63, 1709-1716.
7. Diaz-Rubio, E. (2004). New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 282-294.
8. Dong, Q. G., Sclabas, G. M. and Fujioka, S. (2002). The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21, 6510-6519.
9. Howard, E. W., Lee, D. T., Chiu, Y. T., Chua, C. W., Wang, X. and Wong, Y. C. (2008). Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer. Int. J. Cancer 122, 1941-1948.
10. Hwang, I. K., Woo, K. S., Kim, D. J., Hong, J. T., Hwang, B. Y., Lee, Y. R. and Jeong, H. S. (2007). Isolation and Identification of an Antioxidant Substance from Heated Garlic (Allium sativum L.). Food Sci. Biotechnol. 16, 963-966
11. Kelloff, G. J. (2000). Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. 78, 199-334.
12. Kim, J. H., Xu, C., Keum, Y. S., Reddy, B., Conney, A. and Kong, A. N. (2006) Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27, 475-482.
13. Kim, S. M., Lee, S. Y., Yuk, D. Y., Moon, D. C., Choi, S. S., Kim, Y., Han, S. B., Oh, K. W. and Hong, J. T. (2009). Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch. Pharm. Res. 32, 755-765.
14. Kwon, O. C., Woo, K. S., Kim, T. M., Kim, D. J., Hong, J. T. and Jeong, H. S. (2006). Physicochemical characteristics of garlic (Allium sativum L.) on the high temperature and pressure treatment. Korean J. Food Sci. Technol. 38, 331-336.
15. Millikan, R., Baez, L., Banerjee, T., Wade, J., Edwards, K., Winn, R., Smith, T. L. and Logothetis, C. (2001). Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol. Oncol. 6, 111-115.
16. Nakagawa, H., Tsuta, K., Kiuchi, K., Senzaki, H., Tanaka, K., Hioki, K. and Tsubura, A. (2001). Growth inhibitory effects of diallyl disulfide on human breast cancer cell lines. Carcinogenesis 22, 891-897.
17. Ojima, I., Kuduk, S. D., Slater, J. C., Gimi, R. H. and Sun, C. M. (1996). Syntheses of new fluorine-containing taxoids by means of â-lactam synthon method. Tetrahedron 52, 209-224.
18. Ortiz, M. A., Bayon, Y., Lopez-Hernandez, F. J. and Piedrafita, F. J. (2002). Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. Drug Resist. Updat. 5, 162-175.
19. Palayoor, S. T., Youmell, M. Y., Calderwood, S. K., Coleman, C. N. and Price, B. D. (1999). Constitutive activation of Ikappa B alpha and NF-kappB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18, 7389-7394.
20. Pares, A., Planas, R., Torres, M., Caballeria, J., Viver, J. M., Acero, D., Panes, J., Rigau, J., Santos, J. and Rodes, J. (1998). Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol. 28, 615-621.
21. Qadan, L. R., Perez-Stable, C. M., Anderson, C., D'Ippolito, G., Herron, A., Howard, G. A. and Roos, B. A. (2001). 2-Methoxyestradiol induces G2-M arrest and apoptosis in prostate cancer. Biochem. Biophys. Res. Commun. 285, 1259-1266.
22. Rosenberg, J. E., Ryan, C. J., Weinberg, V. K., Smith, D. C., Hussain, M., Beer, T. M., Ryan, C. W., Mathew, P., Pagliaro, L. C., Harzstark, A. L., Sharib, J. and Small, E. J. (2009). Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J. Clin. Oncol. 27, 2772-2778.
23. Ryan, D. P., Kulke, M. H., Fuchs, C. S., Grossbard, M. L., Grossman, S. R., Morgan, J. A., Earle, C. C., Shivdasani, R., Kim, H., Mayer, R. J. and Clark, J. W. (2002). A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 94, 97-103.
24. Sabayan, B., Foroughinia, F. and Chohedry, A. (2007). A postulated role of garlic organosulfur compounds in prevention of valproic acid hepatotoxicity. Med. Hypotheses. 68, 512-514.
25. Sarafraz, M. and Ahmadi, K. (2008). Paraclinical evaluation of side-effects of Taxanes on auditory system. Acta. Otorhinolaryngol. Ital. 28, 239-242.
26. Scifo, C., Milasi, A., Guarnera, A., Sinatra, F. and Renis, M. (2006). Resveratrol and propolis extract: an insight into the morphological and molecular changes induced in DU145 cells. Oncol. Res. 15, 409-421.
27. Shaikh, I. A., Brown, I., Schofield, A. C., Wahle, K. W. and Heys, S. D. (2008). Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 68, 1635-1646.
28. Shigemura, K., Arbiser, J. L., Sun, S. Y., Zayzafoon, M., Johnstone, P. A., Fujisawa, M., Gotoh, A., Weksler, B., Zhau, H. E. and Chung, L. W. (2007). Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109, 1279-1289.
29. Singh, R. P., Tyagi, A. K., Zhao, J. and Agarwal, R. (2002). Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis Lond. 23, 499-510.
30. Sporn. M. B. and Suh. N. (2000). Chemoprevention of cancer. Carcinogenesis Lond. 21, 525-530.
31. Sun, L. C., Luo, J., Mackey, L. V., Fuselier, J. A. and Coy, D. H. (2007). A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3 K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett. 246, 157-166.
32. Tedesco, K. L., Thor, A. D., Johnson, D. H., Shyr, Y., Blum, K. A., Goldstein, L. J., Gradishar, W. J., Nicholson, B. P., Merkel, D. E., Murrey, D., Edgerton, S. and Sledge, G. W. (2004). Docetaxel combined with trastuzumab is an active regimen in HER-2 3+overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J. Clin. Oncol. 15, 1071-1077.
33. Uzzo, R. G., Leavis, P. and Hatch, W. (2002). Zinc inhibits nuclear factorkappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin. Cancer Res. 8, 3579-3583.
34. Waddick, K. G. and Uckun, F. M. (1999). Innovative treatment programs against cancer: II. Nuclear factor-κB (NF-κB) as a molecular target. Biochem. Pharmacol. 57, 9-17.
35. Wang, C. Y., Mayo, M. W. and Baldwin, A. S. (1996). TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274, 784-787.
36. Wang, W. and Cassidy, J. (2003). Constitutive nuclear factorkappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitorresistant tumour cells. Br. J. Cancer 88, 624-629.
37. Yance, D. R. and Sagar, S. M. (2006). Targeting angiogenesis with integrative cancer therapies. Integr. Cancer Ther. 5, 9-29.
38. Zhang, H., Morisaki, T. and Nakahara, C. (2003). PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22, 2088-2096.